Cargando…
Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
OBJECTIVES: The differential diagnosis of seronegative rheumatoid arthritis (negRA) and psoriasis arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical markers. Since chronic inflammation induces major changes in the serum metabolome and lip...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147174/ https://www.ncbi.nlm.nih.gov/pubmed/32079570 http://dx.doi.org/10.1136/annrheumdis-2019-216374 |
_version_ | 1783520367704276992 |
---|---|
author | Souto-Carneiro, Margarida Tóth, Lilla Behnisch, Rouven Urbach, Konstantin Klika, Karel D Carvalho, Rui A Lorenz, Hanns-Martin |
author_facet | Souto-Carneiro, Margarida Tóth, Lilla Behnisch, Rouven Urbach, Konstantin Klika, Karel D Carvalho, Rui A Lorenz, Hanns-Martin |
author_sort | Souto-Carneiro, Margarida |
collection | PubMed |
description | OBJECTIVES: The differential diagnosis of seronegative rheumatoid arthritis (negRA) and psoriasis arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical markers. Since chronic inflammation induces major changes in the serum metabolome and lipidome, we tested whether differences in serum metabolites and lipids could aid in improving the differential diagnosis of these diseases. METHODS: Sera from negRA and PsA patients with established diagnosis were collected to build a biomarker-discovery cohort and a blinded validation cohort. Samples were analysed by proton nuclear magnetic resonance. Metabolite concentrations were calculated from the spectra and used to select the variables to build a multivariate diagnostic model. RESULTS: Univariate analysis demonstrated differences in serological concentrations of amino acids: alanine, threonine, leucine, phenylalanine and valine; organic compounds: acetate, creatine, lactate and choline; and lipid ratios L3/L1, L5/L1 and L6/L1, but yielded area under the curve (AUC) values lower than 70%, indicating poor specificity and sensitivity. A multivariate diagnostic model that included age, gender, the concentrations of alanine, succinate and creatine phosphate and the lipid ratios L2/L1, L5/L1 and L6/L1 improved the sensitivity and specificity of the diagnosis with an AUC of 84.5%. Using this biomarker model, 71% of patients from a blinded validation cohort were correctly classified. CONCLUSIONS: PsA and negRA have distinct serum metabolomic and lipidomic signatures that can be used as biomarkers to discriminate between them. After validation in larger multiethnic cohorts this diagnostic model may become a valuable tool for a definite diagnosis of negRA or PsA patients. |
format | Online Article Text |
id | pubmed-7147174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-71471742020-04-15 Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis Souto-Carneiro, Margarida Tóth, Lilla Behnisch, Rouven Urbach, Konstantin Klika, Karel D Carvalho, Rui A Lorenz, Hanns-Martin Ann Rheum Dis Psoriatic Arthritis OBJECTIVES: The differential diagnosis of seronegative rheumatoid arthritis (negRA) and psoriasis arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical markers. Since chronic inflammation induces major changes in the serum metabolome and lipidome, we tested whether differences in serum metabolites and lipids could aid in improving the differential diagnosis of these diseases. METHODS: Sera from negRA and PsA patients with established diagnosis were collected to build a biomarker-discovery cohort and a blinded validation cohort. Samples were analysed by proton nuclear magnetic resonance. Metabolite concentrations were calculated from the spectra and used to select the variables to build a multivariate diagnostic model. RESULTS: Univariate analysis demonstrated differences in serological concentrations of amino acids: alanine, threonine, leucine, phenylalanine and valine; organic compounds: acetate, creatine, lactate and choline; and lipid ratios L3/L1, L5/L1 and L6/L1, but yielded area under the curve (AUC) values lower than 70%, indicating poor specificity and sensitivity. A multivariate diagnostic model that included age, gender, the concentrations of alanine, succinate and creatine phosphate and the lipid ratios L2/L1, L5/L1 and L6/L1 improved the sensitivity and specificity of the diagnosis with an AUC of 84.5%. Using this biomarker model, 71% of patients from a blinded validation cohort were correctly classified. CONCLUSIONS: PsA and negRA have distinct serum metabolomic and lipidomic signatures that can be used as biomarkers to discriminate between them. After validation in larger multiethnic cohorts this diagnostic model may become a valuable tool for a definite diagnosis of negRA or PsA patients. BMJ Publishing Group 2020-04 2020-02-20 /pmc/articles/PMC7147174/ /pubmed/32079570 http://dx.doi.org/10.1136/annrheumdis-2019-216374 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Psoriatic Arthritis Souto-Carneiro, Margarida Tóth, Lilla Behnisch, Rouven Urbach, Konstantin Klika, Karel D Carvalho, Rui A Lorenz, Hanns-Martin Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
title | Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
title_full | Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
title_fullStr | Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
title_full_unstemmed | Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
title_short | Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
title_sort | differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis |
topic | Psoriatic Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147174/ https://www.ncbi.nlm.nih.gov/pubmed/32079570 http://dx.doi.org/10.1136/annrheumdis-2019-216374 |
work_keys_str_mv | AT soutocarneiromargarida differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis AT tothlilla differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis AT behnischrouven differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis AT urbachkonstantin differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis AT klikakareld differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis AT carvalhoruia differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis AT lorenzhannsmartin differencesintheserummetabolomeandlipidomeidentifypotentialbiomarkersforseronegativerheumatoidarthritisversuspsoriaticarthritis |